Pasithea Proposes 670% Stock Plan Boost, Reverse Split Ahead of Annual Meeting
Ticker: KTTAW · Form: DEF 14A · Filed: Jul 24, 2025 · CIK: 1841330
| Field | Detail |
|---|---|
| Company | Pasithea Therapeutics CORP. (KTTAW) |
| Form Type | DEF 14A |
| Filed Date | Jul 24, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Reverse Stock Split, Stock Incentive Plan, Shareholder Dilution, Corporate Governance, Pharmaceuticals, SEC Filing, Proxy Statement
Related Tickers: KTTAW
TL;DR
**Pasithea's proposed reverse split and massive stock plan increase reek of desperation to stay listed and dilute shareholders; avoid.**
AI Summary
Pasithea Therapeutics Corp. (KTTAW) has filed a DEF 14A for its Annual Meeting on September 3, 2025, proposing several key changes. The company seeks to elect director nominees and ratify CBIZ CPAs P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant proposal is to amend the 2023 Stock Incentive Plan, increasing the authorized shares for issuance by 1,750,000 to a new total of 2,014,221 shares, representing a substantial 670% increase from the previous 264,221 shares. Furthermore, Pasithea is seeking stockholder approval for a reverse stock split, with a proposed ratio ranging from one-for-two (1:2) to one-for-twenty (1:20), to be implemented within one year of the Annual Meeting. This reverse split aims to increase the per-share trading price, potentially to meet exchange listing requirements. The company's strategic outlook appears focused on maintaining compliance and incentivizing personnel through increased equity compensation.
Why It Matters
This DEF 14A filing signals Pasithea's proactive measures to address potential delisting risks and enhance its equity compensation strategy. A reverse stock split, ranging from 1:2 to 1:20, directly impacts investors by reducing the number of outstanding shares and increasing the per-share price, which could be a double-edged sword for liquidity and market perception. The substantial increase of 1,750,000 shares in the 2023 Stock Incentive Plan, bringing the total to 2,014,221 shares, could dilute existing shareholders but is intended to attract and retain talent in a competitive pharmaceutical industry. For employees, this means more potential equity upside, while customers and the broader market will watch if these moves stabilize the company's financial standing and support its pharmaceutical development.
Risk Assessment
Risk Level: high — The proposal for a reverse stock split, ranging from 1:2 to 1:20, often indicates a company is struggling to maintain its stock price above exchange minimums, signaling underlying operational or financial challenges. Furthermore, the request to increase the 2023 Stock Incentive Plan by 1,750,000 shares to 2,014,221 shares represents a 670% increase in authorized shares for issuance, which could lead to significant shareholder dilution if fully utilized.
Analyst Insight
Investors should carefully evaluate the implications of the proposed reverse stock split on their holdings and consider the potential for significant dilution from the expanded stock incentive plan. Given the high risk, a cautious approach is warranted, and further due diligence into Pasithea's financial health and operational performance is recommended before making any investment decisions.
Key Numbers
- 2,014,221 shares — New maximum shares for 2023 Incentive Plan (Increased by 1,750,000 shares from previous total)
- 1:2 to 1:20 — Reverse stock split ratio range (Proposed to increase per-share trading price)
- 670% — Percentage increase in authorized shares (Represents the increase from previous 264,221 shares to 2,014,221 shares)
- September 3, 2025 — Annual Meeting Date (Key date for stockholder votes on proposals)
- 1 year — Reverse split implementation window (Timeframe for Board to effectuate the reverse stock split)
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant filing DEF 14A
- CBIZ CPAs P.C. (company) — Proposed independent registered public accounting firm
- September 3, 2025 (date) — Date of the Annual Meeting of Stockholders
- 1,750,000 shares (dollar_amount) — Proposed increase in authorized shares for the 2023 Stock Incentive Plan
- 2,014,221 shares (dollar_amount) — New maximum aggregate number of shares for the 2023 Stock Incentive Plan
- one-for-two (1:2) (dollar_amount) — Minimum proposed reverse stock split ratio
- one-for-twenty (1:20) (dollar_amount) — Maximum proposed reverse stock split ratio
- Board of Directors (person) — Approves the reverse stock split
- Miami Beach, Florida (location) — Business address of Pasithea Therapeutics Corp.
- SEC (regulator) — Securities and Exchange Commission
FAQ
What is Pasithea Therapeutics Corp. proposing at its 2025 Annual Meeting?
Pasithea Therapeutics Corp. is proposing the election of director nominees, ratification of CBIZ CPAs P.C. as auditors, an amendment to increase the 2023 Stock Incentive Plan by 1,750,000 shares to 2,014,221 shares, and a reverse stock split ranging from one-for-two (1:2) to one-for-twenty (1:20).
How will the proposed amendment to the 2023 Stock Incentive Plan affect Pasithea Therapeutics Corp. shareholders?
The proposed amendment will increase the maximum aggregate number of shares authorized for issuance under the 2023 Stock Incentive Plan by 1,750,000 shares, bringing the total to 2,014,221 shares. This significant increase, a 670% jump, could lead to substantial dilution for existing shareholders if these shares are fully issued.
What is the purpose of Pasithea Therapeutics Corp.'s proposed reverse stock split?
The primary purpose of Pasithea Therapeutics Corp.'s proposed reverse stock split, with a ratio between 1:2 and 1:20, is likely to increase the per-share trading price of its common stock. This is often done to meet minimum price requirements for continued listing on a stock exchange.
When is Pasithea Therapeutics Corp.'s Annual Meeting of Stockholders?
Pasithea Therapeutics Corp.'s Annual Meeting of Stockholders is scheduled to be held in a virtual format on September 3, 2025, at 9:00 AM Eastern Time.
Who is Pasithea Therapeutics Corp.'s proposed independent registered public accounting firm for 2025?
Pasithea Therapeutics Corp. is seeking stockholder ratification for the appointment of CBIZ CPAs P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
What are the potential risks associated with Pasithea Therapeutics Corp.'s proposed reverse stock split?
A reverse stock split, while increasing the per-share price, does not change the company's underlying value or market capitalization. It can sometimes be perceived negatively by investors, potentially leading to further stock price declines or reduced liquidity, and often signals financial distress or difficulty maintaining exchange listing requirements.
What is the current number of shares authorized for the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan before the proposed amendment?
Before the proposed amendment, the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan authorized 264,221 shares of common stock for issuance.
Who has the discretion to effectuate the reverse stock split for Pasithea Therapeutics Corp.?
The Board of Directors of Pasithea Therapeutics Corp. has the discretion to effectuate the reverse stock split at any time prior to the one-year anniversary date of the Annual Meeting, if approved by stockholders.
What is the business address of Pasithea Therapeutics Corp.?
The business address for Pasithea Therapeutics Corp. is 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139.
Why is Pasithea Therapeutics Corp. increasing its stock incentive plan?
Pasithea Therapeutics Corp. is increasing its stock incentive plan to provide additional equity compensation for its employees, directors, and consultants. This is a common strategy to attract, retain, and motivate key personnel by aligning their interests with those of the shareholders.
Risk Factors
- Reverse Stock Split to Address Low Share Price [medium — financial]: The company is proposing a reverse stock split with a ratio ranging from 1:2 to 1:20. This action is intended to increase the per-share trading price of its common stock, potentially to meet stock exchange listing requirements. The Board has discretion to implement this within one year of the Annual Meeting.
- Significant Increase in Equity Compensation Pool [medium — financial]: Pasithea Therapeutics is seeking to increase the authorized shares for its 2023 Stock Incentive Plan by 1,750,000 shares, bringing the total to 2,014,221 shares. This represents a 670% increase from the previous 264,221 shares, indicating a strong reliance on equity-based incentives for personnel.
- Potential Delisting Risk [high — regulatory]: The proposed reverse stock split is a direct response to a low per-share trading price, which may be a precursor to or a consequence of not meeting stock exchange listing standards. Failure to maintain listing requirements could lead to delisting, significantly impacting liquidity and investor confidence.
Industry Context
Pasithea Therapeutics operates in the pharmaceutical preparations sector, a highly competitive industry characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often face challenges related to drug efficacy, clinical trial success, patent expirations, and market access. The industry is driven by innovation, with a constant need to bring new therapies to market to address unmet medical needs.
Regulatory Implications
The proposed reverse stock split is a measure to comply with stock exchange listing requirements, which are critical for maintaining the company's public trading status. Failure to meet these requirements could lead to delisting, impacting liquidity and investor confidence. The increase in the stock incentive plan also falls under regulatory scrutiny regarding executive and employee compensation disclosures.
What Investors Should Do
- Review the details of the proposed reverse stock split ratio and its potential impact on share price and liquidity.
- Evaluate the significant increase in authorized shares for the 2023 Stock Incentive Plan.
- Consider the company's financial health and strategic rationale for these proposals.
Key Dates
- 2025-09-03: Annual Meeting of Stockholders — Key date for stockholder votes on director elections, auditor ratification, stock incentive plan amendment, and reverse stock split proposal.
- 2025-12-31: Fiscal Year End — The period for which CBIZ CPAs P.C. is proposed to be ratified as the independent registered public accounting firm.
- 2026-09-03: One-year anniversary of Annual Meeting — Deadline for the Board of Directors to implement the reverse stock split, if approved.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by a company soliciting shareholder votes. (This document outlines the proposals being voted on at the Annual Meeting, including director elections and corporate actions.)
- Reverse Stock Split
- A corporate action where a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (Pasithea Therapeutics is proposing this to increase its per-share trading price, likely to meet exchange listing requirements.)
- 2023 Stock Incentive Plan
- A plan established by the company to grant equity-based compensation, such as stock options or restricted stock, to employees and directors. (The company is seeking to significantly increase the number of shares available under this plan to provide future equity incentives.)
- Independent Registered Public Accounting Firm
- An external audit firm hired by a company to conduct an independent audit of its financial statements. (The shareholders are being asked to ratify the appointment of CBIZ CPAs P.C. for the upcoming fiscal year.)
Year-Over-Year Comparison
This DEF 14A filing focuses on upcoming annual meeting proposals, including a significant increase in the stock incentive plan shares (by 1,750,000 to 2,014,221, a 670% rise) and a proposed reverse stock split. Specific financial metrics and comparisons to prior periods are not detailed within this proxy statement itself, as it is primarily a solicitation for shareholder votes on corporate actions rather than a comprehensive financial report. Therefore, direct year-over-year comparisons of revenue, margins, or net income are not available from this document.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 24, 2025 by Board of Directors regarding Pasithea Therapeutics Corp. (KTTAW).